$-2.57
(Market cap
$2,576 Mln
Revenue (TTM)
$458 Mln
P/E Ratio
23.9
P/B Ratio
6.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
0.3 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
151.3
-
Debt to Equity
0
-
Book Value
$8.3
-
EPS
$2.1
-
Face value
--
-
Shares outstanding
51,734,223
10 Years Aggregate
CFO
$-80.20 Mln
EBITDA
$-303.80 Mln
Net Profit
$-492.86 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Caredx Inc (CDNA)
| 164.3 | 36.9 | 124.7 | 274.6 | 78.7 | -9.0 | 25.9 |
|
BSE Sensex
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Caredx Inc (CDNA)
| -12.0 | 77.6 | 5.2 | -74.9 | -37.2 | 235.9 | -14.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Caredx Inc (CDNA)
|
49.8 | 2,575.9 | 458.1 | 111.0 | -0.9 | 30.5 | 23.9 | 6.4 |
| 84.9 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 247.9 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.1 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 54.5 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 105.4 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 351.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 533.8 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 600.7 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 344.8 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout Caredx Inc (CDNA)
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney... transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California. Read more
-
CFO & Principal Accounting Officer
Mr. Abhishek Jain
-
CFO & Principal Accounting Officer
Mr. Abhishek Jain
-
Headquarters
Brisbane, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Caredx Inc (CDNA)
What is the current share price of Caredx Inc (CDNA) Today?
The share price of Caredx Inc (CDNA) is $49.79 (NASDAQ) as of 28-Aug-2026 16:15 EDT. Caredx Inc (CDNA) has given a return of 78.67% in the last 3 years.
What is the current PB & PE ratio of Caredx Inc (CDNA)?
The P/E ratio of Caredx Inc (CDNA) is 23.94 times as on 28-Aug-2026.
The P/B ratio of Caredx Inc (CDNA) is 6.36 times as on 28-Aug-2026, a 19 premium to its peers’ median range of 5.35 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-45.11 |
3.18 |
2024 |
23.72 |
3.29 |
2023 |
-3.33 |
2.42 |
2022 |
-7.97 |
1.42 |
2021 |
-78.40 |
5.16 |
What is the 52 Week High and Low of Caredx Inc (CDNA)?
The 52-week high and low of Caredx Inc (CDNA) are Rs 53.67 and Rs 12.65 as of 30-Aug-2026.
What is the market cap of Caredx Inc (CDNA)?
Caredx Inc (CDNA) has a market capitalisation of $ 2,576 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Caredx Inc (CDNA)?
Before investing in Caredx Inc (CDNA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.